市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Moderna, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-1.8
| 分析师共识 | NA |
| 内部交易活动 | -5.0 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -1.75 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 7.28% |
| 机构持股比例 | 73.67% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Baillie Gifford & Co | 30 Jun 2026 | 18,206,778 |
| Theleme Partners Llp | 30 Jun 2026 | 8,057,571 |
| Two Sigma Advisers, Lp | 31 Dec 2025 | 7,729,700 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HOGE STEPHEN | - | 145.23 | -80,575 | -11,701,926 |
| MOCK JAMES M | - | 136.62 | -34,836 | -4,759,294 |
| 累积净数量 | -115,411 | |||
| 累积净值 ($) | -16,461,221 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 142.36 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HOGE STEPHEN | 职员 | 15 Sep 2026 | 自动卖出 (-) | 40,281 | 143.77 | 5,791,199 |
| HOGE STEPHEN | 职员 | 15 Sep 2026 | 执行期权 | 76,452 | - | - |
| HOGE STEPHEN | 职员 | 14 Sep 2026 | 自动卖出 (-) | 40,294 | 146.69 | 5,910,727 |
| HOGE STEPHEN | 职员 | 14 Sep 2026 | 执行期权 | 76,453 | - | - |
| MOCK JAMES M | 职员 | 10 Sep 2026 | 自动卖出 (-) | 34,836 | 136.62 | 4,759,294 |
| MOCK JAMES M | 职员 | 10 Sep 2026 | 执行期权 | 19,836 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合